 Anna Bruckner
Concepts (456)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epidermolysis Bullosa | 31 | 2025 | 59 | 7.730 |
Why?
| | Epidermolysis Bullosa Dystrophica | 15 | 2025 | 40 | 3.190 |
Why?
| | Hemangioma | 9 | 2016 | 44 | 2.660 |
Why?
| | Dermatology | 7 | 2024 | 117 | 2.370 |
Why?
| | Skin Neoplasms | 12 | 2024 | 824 | 1.780 |
Why?
| | Collagen Type VII | 5 | 2025 | 27 | 1.610 |
Why?
| | Acne Vulgaris | 2 | 2022 | 27 | 1.180 |
Why?
| | Skin | 9 | 2024 | 726 | 1.060 |
Why?
| | Dermatologic Agents | 3 | 2025 | 65 | 0.870 |
Why?
| | Lymphatic Abnormalities | 2 | 2014 | 19 | 0.820 |
Why?
| | Ichthyosis, Lamellar | 3 | 2022 | 9 | 0.770 |
Why?
| | Child | 45 | 2025 | 20773 | 0.750 |
Why?
| | Gentamicins | 1 | 2022 | 54 | 0.750 |
Why?
| | Infant | 27 | 2025 | 8975 | 0.740 |
Why?
| | Humans | 102 | 2025 | 129248 | 0.730 |
Why?
| | Betacoronavirus | 2 | 2020 | 248 | 0.710 |
Why?
| | Chilblains | 1 | 2020 | 3 | 0.700 |
Why?
| | Alopecia | 2 | 2012 | 30 | 0.690 |
Why?
| | Dermatitis, Allergic Contact | 4 | 2002 | 70 | 0.670 |
Why?
| | Severity of Illness Index | 8 | 2025 | 2737 | 0.670 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2020 | 38 | 0.650 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2020 | 56 | 0.640 |
Why?
| | Exanthema | 1 | 2020 | 74 | 0.630 |
Why?
| | Isotretinoin | 2 | 2022 | 23 | 0.630 |
Why?
| | Diagnosis, Differential | 13 | 2015 | 1430 | 0.620 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 339 | 0.610 |
Why?
| | Coronavirus Infections | 2 | 2020 | 333 | 0.610 |
Why?
| | Pandemics | 4 | 2023 | 1482 | 0.600 |
Why?
| | Skin Diseases | 3 | 2011 | 143 | 0.590 |
Why?
| | Mandelic Acids | 1 | 2018 | 2 | 0.590 |
Why?
| | Parasympatholytics | 1 | 2018 | 12 | 0.580 |
Why?
| | Hyperhidrosis | 1 | 2018 | 4 | 0.580 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 160 | 0.580 |
Why?
| | GTP-Binding Protein alpha Subunits | 2 | 2016 | 14 | 0.560 |
Why?
| | Education, Distance | 1 | 2017 | 43 | 0.550 |
Why?
| | Child, Preschool | 21 | 2025 | 10456 | 0.550 |
Why?
| | Dermatitis, Atopic | 2 | 2017 | 319 | 0.530 |
Why?
| | Vascular Neoplasms | 2 | 2016 | 17 | 0.530 |
Why?
| | Telemedicine | 2 | 2023 | 789 | 0.530 |
Why?
| | Adolescent | 25 | 2025 | 20303 | 0.510 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2016 | 55 | 0.510 |
Why?
| | Histiocytosis | 1 | 2015 | 7 | 0.500 |
Why?
| | Male | 48 | 2025 | 63501 | 0.500 |
Why?
| | Epidermolysis Bullosa, Junctional | 3 | 2021 | 3 | 0.500 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2015 | 25 | 0.490 |
Why?
| | Consensus | 5 | 2024 | 615 | 0.480 |
Why?
| | Female | 45 | 2025 | 68543 | 0.470 |
Why?
| | Alopecia Areata | 2 | 2022 | 10 | 0.470 |
Why?
| | Rare Diseases | 1 | 2015 | 98 | 0.470 |
Why?
| | Nevus, Pigmented | 1 | 2015 | 32 | 0.470 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2015 | 36 | 0.460 |
Why?
| | Anemia | 5 | 2023 | 160 | 0.460 |
Why?
| | Thrombocytopenia | 2 | 2016 | 186 | 0.460 |
Why?
| | Endothelium, Lymphatic | 1 | 2014 | 12 | 0.450 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2014 | 22 | 0.450 |
Why?
| | Sweat Gland Neoplasms | 2 | 2011 | 5 | 0.440 |
Why?
| | Hydrops Fetalis | 1 | 2014 | 13 | 0.440 |
Why?
| | Drug Eruptions | 1 | 2013 | 27 | 0.440 |
Why?
| | Epidermolysis Bullosa Simplex | 3 | 2023 | 10 | 0.430 |
Why?
| | Propranolol | 2 | 2011 | 50 | 0.420 |
Why?
| | Infant, Newborn | 14 | 2024 | 5736 | 0.420 |
Why?
| | Hemangioendothelioma | 1 | 2012 | 15 | 0.400 |
Why?
| | Kasabach-Merritt Syndrome | 1 | 2012 | 7 | 0.400 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2013 | 145 | 0.400 |
Why?
| | Langer-Giedion Syndrome | 1 | 2012 | 2 | 0.390 |
Why?
| | Internship and Residency | 2 | 2022 | 1047 | 0.390 |
Why?
| | Hair Diseases | 1 | 2012 | 9 | 0.390 |
Why?
| | Bone Demineralization, Pathologic | 1 | 2011 | 2 | 0.380 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2012 | 37 | 0.380 |
Why?
| | Mutation | 7 | 2025 | 3710 | 0.380 |
Why?
| | Sarcoma, Kaposi | 1 | 2012 | 76 | 0.380 |
Why?
| | Clinical Competence | 2 | 2022 | 1016 | 0.370 |
Why?
| | Ichthyosis | 2 | 2022 | 12 | 0.370 |
Why?
| | Calcification, Physiologic | 1 | 2011 | 33 | 0.370 |
Why?
| | Microscopy, Fluorescence | 1 | 2013 | 398 | 0.360 |
Why?
| | Sulfones | 1 | 2012 | 108 | 0.360 |
Why?
| | Bone Diseases, Metabolic | 2 | 2011 | 57 | 0.360 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2014 | 443 | 0.360 |
Why?
| | 2-Propanol | 1 | 2011 | 22 | 0.360 |
Why?
| | Facial Neoplasms | 1 | 2011 | 18 | 0.360 |
Why?
| | Facial Dermatoses | 2 | 2010 | 16 | 0.350 |
Why?
| | Bone Density | 2 | 2011 | 462 | 0.350 |
Why?
| | Dermis | 2 | 2011 | 31 | 0.350 |
Why?
| | Gene Deletion | 1 | 2012 | 380 | 0.350 |
Why?
| | Hyperpigmentation | 1 | 2011 | 25 | 0.350 |
Why?
| | Genes, Recessive | 3 | 2025 | 76 | 0.340 |
Why?
| | Solvents | 1 | 2011 | 108 | 0.340 |
Why?
| | Ferrochelatase | 1 | 2010 | 1 | 0.340 |
Why?
| | Porphyria, Erythropoietic | 1 | 2010 | 2 | 0.340 |
Why?
| | Young Adult | 14 | 2025 | 12388 | 0.340 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2276 | 0.340 |
Why?
| | Tumor Burden | 1 | 2011 | 286 | 0.340 |
Why?
| | Desmoplakins | 1 | 2010 | 19 | 0.340 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2010 | 16 | 0.340 |
Why?
| | Laryngeal Neoplasms | 1 | 2010 | 31 | 0.330 |
Why?
| | Xanthomatosis | 1 | 2009 | 11 | 0.330 |
Why?
| | Mediastinal Neoplasms | 1 | 2010 | 38 | 0.330 |
Why?
| | Immunohistochemistry | 5 | 2019 | 1691 | 0.320 |
Why?
| | Granuloma | 1 | 2010 | 89 | 0.320 |
Why?
| | Piperazines | 1 | 2012 | 341 | 0.320 |
Why?
| | Carcinoma | 1 | 2011 | 215 | 0.310 |
Why?
| | Parakeratosis | 1 | 2008 | 1 | 0.300 |
Why?
| | Pruritus | 3 | 2014 | 58 | 0.300 |
Why?
| | Canada | 3 | 2020 | 350 | 0.280 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2010 | 321 | 0.280 |
Why?
| | Self-Help Groups | 1 | 2007 | 34 | 0.270 |
Why?
| | Dermatitis, Exfoliative | 1 | 2006 | 4 | 0.270 |
Why?
| | Hand Dermatoses | 1 | 2006 | 7 | 0.270 |
Why?
| | Wound Healing | 3 | 2025 | 305 | 0.270 |
Why?
| | Immunoglobulin A | 3 | 2018 | 200 | 0.260 |
Why?
| | Ethics, Medical | 1 | 2007 | 78 | 0.260 |
Why?
| | Prospective Studies | 4 | 2022 | 7121 | 0.250 |
Why?
| | Pemphigus | 1 | 2005 | 8 | 0.250 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2022 | 625 | 0.240 |
Why?
| | Hamartoma | 1 | 2005 | 20 | 0.240 |
Why?
| | Netherton Syndrome | 1 | 2025 | 3 | 0.240 |
Why?
| | Ichthyosiform Erythroderma, Congenital | 1 | 2025 | 6 | 0.240 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1267 | 0.240 |
Why?
| | Biopsy, Needle | 3 | 2019 | 189 | 0.230 |
Why?
| | Phytotherapy | 1 | 2025 | 79 | 0.230 |
Why?
| | Observer Variation | 4 | 2022 | 315 | 0.230 |
Why?
| | Homozygote | 1 | 2025 | 193 | 0.230 |
Why?
| | Incontinentia Pigmenti | 1 | 2004 | 3 | 0.230 |
Why?
| | Transcription Factors | 1 | 2012 | 1647 | 0.220 |
Why?
| | Sarcoma, Clear Cell | 1 | 2024 | 8 | 0.220 |
Why?
| | Pediatrics | 1 | 2012 | 1047 | 0.220 |
Why?
| | Introns | 1 | 2025 | 251 | 0.220 |
Why?
| | Biopsy | 3 | 2015 | 1091 | 0.220 |
Why?
| | Organic Chemicals | 1 | 2025 | 123 | 0.220 |
Why?
| | Scalp | 1 | 2024 | 34 | 0.220 |
Why?
| | North America | 3 | 2021 | 291 | 0.220 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2024 | 76 | 0.220 |
Why?
| | Retrospective Studies | 13 | 2025 | 14455 | 0.210 |
Why?
| | Immunoglobulin G | 3 | 2018 | 848 | 0.210 |
Why?
| | Treatment Outcome | 9 | 2025 | 10199 | 0.210 |
Why?
| | Aspirin | 1 | 2006 | 380 | 0.210 |
Why?
| | Administration, Topical | 3 | 2020 | 145 | 0.210 |
Why?
| | Water | 1 | 2006 | 440 | 0.210 |
Why?
| | Privacy | 1 | 2023 | 32 | 0.210 |
Why?
| | Plant Extracts | 1 | 2025 | 198 | 0.210 |
Why?
| | Transition to Adult Care | 1 | 2024 | 79 | 0.210 |
Why?
| | Genetic Association Studies | 1 | 2025 | 361 | 0.200 |
Why?
| | Decision Support Techniques | 1 | 2007 | 395 | 0.200 |
Why?
| | Triterpenes | 1 | 2023 | 20 | 0.200 |
Why?
| | Confidentiality | 1 | 2023 | 67 | 0.200 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2006 | 442 | 0.200 |
Why?
| | Phenotype | 3 | 2025 | 3074 | 0.200 |
Why?
| | Delphi Technique | 1 | 2024 | 225 | 0.200 |
Why?
| | Skin Care | 2 | 2020 | 21 | 0.200 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2022 | 20 | 0.190 |
Why?
| | Cohort Studies | 4 | 2022 | 5408 | 0.190 |
Why?
| | Competency-Based Education | 1 | 2022 | 71 | 0.190 |
Why?
| | Quality of Life | 4 | 2025 | 2685 | 0.190 |
Why?
| | Jews | 1 | 2021 | 19 | 0.190 |
Why?
| | Anesthetics | 1 | 2022 | 66 | 0.190 |
Why?
| | Biological Products | 1 | 2025 | 200 | 0.190 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2024 | 221 | 0.180 |
Why?
| | Administration, Intravenous | 1 | 2022 | 141 | 0.180 |
Why?
| | Rhabdomyosarcoma | 1 | 2022 | 64 | 0.180 |
Why?
| | Fatal Outcome | 2 | 2014 | 299 | 0.180 |
Why?
| | Adrenal Cortex Hormones | 2 | 2014 | 522 | 0.180 |
Why?
| | Adult | 16 | 2025 | 35495 | 0.180 |
Why?
| | Toes | 1 | 2020 | 15 | 0.170 |
Why?
| | Follow-Up Studies | 4 | 2019 | 4886 | 0.170 |
Why?
| | Pseudomonas aeruginosa | 1 | 2023 | 347 | 0.170 |
Why?
| | Palliative Care | 1 | 2007 | 706 | 0.170 |
Why?
| | Absorptiometry, Photon | 2 | 2011 | 248 | 0.170 |
Why?
| | NF-kappa B | 1 | 2004 | 665 | 0.170 |
Why?
| | Detergents | 1 | 2020 | 44 | 0.170 |
Why?
| | Iron | 3 | 2023 | 281 | 0.160 |
Why?
| | Mouth Diseases | 2 | 2013 | 43 | 0.160 |
Why?
| | Kidney Neoplasms | 1 | 2024 | 348 | 0.160 |
Why?
| | Mycoplasma pneumoniae | 1 | 2020 | 56 | 0.160 |
Why?
| | Mouth Mucosa | 2 | 2013 | 88 | 0.160 |
Why?
| | Prenatal Diagnosis | 2 | 2014 | 190 | 0.160 |
Why?
| | APOBEC Deaminases | 1 | 2018 | 5 | 0.150 |
Why?
| | Cytosine Deaminase | 1 | 2018 | 15 | 0.150 |
Why?
| | Chronic Pain | 1 | 2022 | 252 | 0.150 |
Why?
| | Linear IgA Bullous Dermatosis | 1 | 2018 | 1 | 0.150 |
Why?
| | Administration, Oral | 2 | 2012 | 785 | 0.150 |
Why?
| | Dilatation | 1 | 2018 | 59 | 0.150 |
Why?
| | Esophageal Stenosis | 1 | 2018 | 51 | 0.150 |
Why?
| | Education, Medical, Graduate | 1 | 2022 | 438 | 0.150 |
Why?
| | Fluoroscopy | 1 | 2018 | 156 | 0.150 |
Why?
| | Age Distribution | 1 | 2019 | 372 | 0.140 |
Why?
| | Sex Distribution | 1 | 2019 | 359 | 0.140 |
Why?
| | Patient Satisfaction | 1 | 2022 | 632 | 0.140 |
Why?
| | Cost of Illness | 1 | 2020 | 277 | 0.140 |
Why?
| | Surveys and Questionnaires | 5 | 2024 | 5382 | 0.140 |
Why?
| | Esophagoscopy | 1 | 2018 | 199 | 0.140 |
Why?
| | Middle Aged | 9 | 2025 | 31087 | 0.130 |
Why?
| | Databases, Factual | 2 | 2020 | 1266 | 0.130 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2016 | 33 | 0.130 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2016 | 19 | 0.130 |
Why?
| | Incidence | 2 | 2022 | 2636 | 0.130 |
Why?
| | Staphylococcal Infections | 1 | 2020 | 389 | 0.130 |
Why?
| | Risk Assessment | 3 | 2019 | 3233 | 0.120 |
Why?
| | Survival Analysis | 1 | 2019 | 1269 | 0.120 |
Why?
| | Clobetasol | 1 | 2015 | 7 | 0.120 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2022 | 592 | 0.120 |
Why?
| | Patient Care Team | 1 | 2020 | 601 | 0.120 |
Why?
| | Pachyonychia Congenita | 1 | 2015 | 4 | 0.120 |
Why?
| | Double-Blind Method | 3 | 2025 | 1875 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2016 | 311 | 0.120 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 313 | 0.110 |
Why?
| | Keratins | 1 | 2015 | 175 | 0.110 |
Why?
| | United States | 4 | 2021 | 13828 | 0.110 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 166 | 0.110 |
Why?
| | Antigens, CD34 | 1 | 2014 | 88 | 0.110 |
Why?
| | Prednisolone | 2 | 2013 | 82 | 0.110 |
Why?
| | Disease Progression | 2 | 2019 | 2630 | 0.110 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1837 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 3 | 2014 | 480 | 0.100 |
Why?
| | Pemphigoid, Bullous | 1 | 2013 | 8 | 0.100 |
Why?
| | Fluorescent Antibody Technique | 2 | 2021 | 376 | 0.100 |
Why?
| | Remission, Spontaneous | 1 | 2012 | 37 | 0.100 |
Why?
| | Transcriptome | 2 | 2018 | 874 | 0.100 |
Why?
| | Skin Diseases, Papulosquamous | 1 | 2012 | 2 | 0.100 |
Why?
| | Pilot Projects | 1 | 2018 | 1584 | 0.100 |
Why?
| | Erythema | 3 | 2022 | 28 | 0.100 |
Why?
| | Caregivers | 1 | 2020 | 808 | 0.100 |
Why?
| | Prednisone | 2 | 2005 | 233 | 0.100 |
Why?
| | Oropharynx | 1 | 2012 | 44 | 0.100 |
Why?
| | Sildenafil Citrate | 1 | 2012 | 59 | 0.090 |
Why?
| | Panniculitis | 1 | 2011 | 2 | 0.090 |
Why?
| | Actins | 1 | 2014 | 411 | 0.090 |
Why?
| | Nose | 1 | 2012 | 63 | 0.090 |
Why?
| | Carcinoma, Verrucous | 1 | 2011 | 2 | 0.090 |
Why?
| | Fingers | 1 | 2012 | 86 | 0.090 |
Why?
| | Age Determination by Skeleton | 1 | 2011 | 17 | 0.090 |
Why?
| | Blood Sedimentation | 1 | 2011 | 34 | 0.090 |
Why?
| | Fractures, Compression | 1 | 2011 | 18 | 0.090 |
Why?
| | Dwarfism | 1 | 2011 | 15 | 0.090 |
Why?
| | Calcifediol | 1 | 2011 | 31 | 0.090 |
Why?
| | Subcutaneous Fat | 1 | 2011 | 74 | 0.090 |
Why?
| | Mobility Limitation | 1 | 2011 | 60 | 0.090 |
Why?
| | Purines | 1 | 2012 | 172 | 0.090 |
Why?
| | Vincristine | 1 | 2011 | 108 | 0.090 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 1702 | 0.090 |
Why?
| | Body Height | 1 | 2011 | 192 | 0.090 |
Why?
| | Darier Disease | 1 | 2010 | 2 | 0.090 |
Why?
| | RNA, Messenger | 2 | 2015 | 2703 | 0.090 |
Why?
| | Hypothermia, Induced | 1 | 2011 | 76 | 0.090 |
Why?
| | Glucocorticoids | 1 | 2015 | 578 | 0.090 |
Why?
| | Body Size | 1 | 2011 | 104 | 0.090 |
Why?
| | Spinal Fractures | 1 | 2011 | 82 | 0.090 |
Why?
| | Serum Albumin | 1 | 2011 | 148 | 0.090 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2010 | 37 | 0.090 |
Why?
| | Steroids | 1 | 2011 | 158 | 0.080 |
Why?
| | Drug Therapy, Combination | 2 | 2011 | 1040 | 0.080 |
Why?
| | Porphyrins | 1 | 2010 | 21 | 0.080 |
Why?
| | Autoantibodies | 1 | 2018 | 1467 | 0.080 |
Why?
| | Patch Tests | 2 | 2001 | 56 | 0.080 |
Why?
| | Sequence Analysis, DNA | 2 | 2010 | 776 | 0.080 |
Why?
| | Keratinocytes | 2 | 2024 | 242 | 0.080 |
Why?
| | Consanguinity | 1 | 2010 | 47 | 0.080 |
Why?
| | Clarithromycin | 1 | 2010 | 28 | 0.080 |
Why?
| | Erythromycin | 1 | 2010 | 24 | 0.080 |
Why?
| | Infant, Newborn, Diseases | 1 | 2011 | 110 | 0.080 |
Why?
| | Foam Cells | 1 | 2009 | 15 | 0.080 |
Why?
| | Ointments | 2 | 2023 | 24 | 0.080 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2015 | 572 | 0.080 |
Why?
| | Porokeratosis | 1 | 2009 | 1 | 0.080 |
Why?
| | Nevus, Intradermal | 1 | 2009 | 3 | 0.080 |
Why?
| | Keratosis | 1 | 2009 | 16 | 0.080 |
Why?
| | Sequence Deletion | 1 | 2010 | 179 | 0.080 |
Why?
| | Staining and Labeling | 1 | 2010 | 141 | 0.080 |
Why?
| | Radiography | 1 | 2012 | 794 | 0.080 |
Why?
| | Basement Membrane | 2 | 2007 | 31 | 0.080 |
Why?
| | Epidermodysplasia Verruciformis | 1 | 2009 | 1 | 0.080 |
Why?
| | Lumbar Vertebrae | 1 | 2011 | 231 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1276 | 0.080 |
Why?
| | Respiratory Sounds | 1 | 2010 | 118 | 0.080 |
Why?
| | Hemoglobins | 1 | 2011 | 339 | 0.080 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2010 | 157 | 0.080 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2011 | 307 | 0.080 |
Why?
| | Dapsone | 2 | 2005 | 7 | 0.080 |
Why?
| | C-Reactive Protein | 1 | 2011 | 400 | 0.080 |
Why?
| | Diaper Rash | 1 | 2008 | 4 | 0.080 |
Why?
| | Blister | 3 | 2013 | 41 | 0.080 |
Why?
| | Immune System Diseases | 1 | 2008 | 34 | 0.070 |
Why?
| | Airway Obstruction | 1 | 2010 | 152 | 0.070 |
Why?
| | Psychophysiologic Disorders | 1 | 2007 | 10 | 0.070 |
Why?
| | Hair | 1 | 2008 | 73 | 0.070 |
Why?
| | Biomedical Research | 1 | 2014 | 637 | 0.070 |
Why?
| | Weight Gain | 1 | 2011 | 509 | 0.070 |
Why?
| | Endothelium, Vascular | 1 | 2014 | 901 | 0.070 |
Why?
| | Models, Theoretical | 1 | 2011 | 546 | 0.070 |
Why?
| | Anti-Anxiety Agents | 1 | 2007 | 45 | 0.070 |
Why?
| | Euthanasia, Passive | 1 | 2007 | 2 | 0.070 |
Why?
| | Ethics Committees | 1 | 2007 | 4 | 0.070 |
Why?
| | Androgens | 1 | 2008 | 178 | 0.070 |
Why?
| | Hematinics | 1 | 2006 | 20 | 0.070 |
Why?
| | Interdisciplinary Communication | 2 | 2020 | 184 | 0.070 |
Why?
| | Patient Advocacy | 1 | 2007 | 73 | 0.070 |
Why?
| | Ferric Compounds | 1 | 2006 | 46 | 0.060 |
Why?
| | Liver Neoplasms | 1 | 2011 | 640 | 0.060 |
Why?
| | Erythropoietin | 1 | 2006 | 88 | 0.060 |
Why?
| | Antidepressive Agents | 1 | 2007 | 228 | 0.060 |
Why?
| | California | 1 | 2007 | 400 | 0.060 |
Why?
| | Professional-Family Relations | 1 | 2007 | 142 | 0.060 |
Why?
| | Desmoglein 3 | 1 | 2005 | 15 | 0.060 |
Why?
| | Antipsychotic Agents | 1 | 2007 | 195 | 0.060 |
Why?
| | Plant Bark | 1 | 2025 | 11 | 0.060 |
Why?
| | Aged | 3 | 2020 | 22032 | 0.060 |
Why?
| | Skin Diseases, Vesiculobullous | 1 | 2005 | 17 | 0.060 |
Why?
| | Genetic Therapy | 1 | 2007 | 288 | 0.060 |
Why?
| | Physicians | 1 | 2014 | 859 | 0.060 |
Why?
| | Fibroblasts | 2 | 2024 | 947 | 0.060 |
Why?
| | Social Environment | 1 | 2007 | 293 | 0.060 |
Why?
| | Colonic Diseases | 1 | 2005 | 32 | 0.060 |
Why?
| | Cellulitis | 1 | 2005 | 48 | 0.060 |
Why?
| | Dermatitis Herpetiformis | 1 | 2004 | 1 | 0.060 |
Why?
| | Calcium | 1 | 2011 | 1212 | 0.060 |
Why?
| | Reproducibility of Results | 3 | 2022 | 3079 | 0.060 |
Why?
| | Epidermis | 1 | 2005 | 155 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1497 | 0.060 |
Why?
| | Immunosuppressive Agents | 2 | 2015 | 854 | 0.060 |
Why?
| | Urticaria | 1 | 2004 | 37 | 0.050 |
Why?
| | Neutrophils | 1 | 2009 | 1207 | 0.050 |
Why?
| | Skin Transplantation | 1 | 2024 | 84 | 0.050 |
Why?
| | Gene Editing | 1 | 2024 | 67 | 0.050 |
Why?
| | Anthraquinones | 1 | 2023 | 10 | 0.050 |
Why?
| | Transplantation, Autologous | 1 | 2024 | 211 | 0.050 |
Why?
| | Pregnancy | 2 | 2014 | 6391 | 0.050 |
Why?
| | CRISPR-Cas Systems | 1 | 2024 | 108 | 0.050 |
Why?
| | Excipients | 1 | 2023 | 52 | 0.050 |
Why?
| | Antibodies | 1 | 2005 | 398 | 0.050 |
Why?
| | Betula | 1 | 2023 | 3 | 0.050 |
Why?
| | Catastrophization | 1 | 2022 | 12 | 0.050 |
Why?
| | Social Support | 1 | 2007 | 582 | 0.050 |
Why?
| | Eosinophilia | 1 | 2005 | 204 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 833 | 0.050 |
Why?
| | Histamine H1 Antagonists | 1 | 2002 | 29 | 0.050 |
Why?
| | Algorithms | 2 | 2007 | 1613 | 0.050 |
Why?
| | Communicable Disease Control | 1 | 2023 | 73 | 0.050 |
Why?
| | Family | 1 | 2007 | 644 | 0.050 |
Why?
| | Professionalism | 1 | 2022 | 18 | 0.050 |
Why?
| | Autoantigens | 1 | 2005 | 419 | 0.050 |
Why?
| | Mucous Membrane | 2 | 2014 | 122 | 0.050 |
Why?
| | Atrophy | 2 | 2013 | 171 | 0.050 |
Why?
| | Accreditation | 1 | 2022 | 80 | 0.050 |
Why?
| | Prevalence | 2 | 2022 | 2554 | 0.050 |
Why?
| | Germ Cells | 1 | 2022 | 59 | 0.050 |
Why?
| | Chile | 1 | 2021 | 20 | 0.050 |
Why?
| | Colombia | 1 | 2021 | 36 | 0.050 |
Why?
| | Photography | 1 | 2022 | 93 | 0.050 |
Why?
| | Tertiary Care Centers | 1 | 2022 | 146 | 0.050 |
Why?
| | Blood Protein Electrophoresis | 1 | 1981 | 8 | 0.050 |
Why?
| | Nephelometry and Turbidimetry | 1 | 1981 | 13 | 0.040 |
Why?
| | Social Class | 1 | 2023 | 258 | 0.040 |
Why?
| | Information Dissemination | 1 | 2023 | 205 | 0.040 |
Why?
| | Mupirocin | 1 | 2020 | 7 | 0.040 |
Why?
| | Mexico | 1 | 2021 | 190 | 0.040 |
Why?
| | Educational Status | 1 | 2023 | 469 | 0.040 |
Why?
| | Retinoids | 1 | 2020 | 33 | 0.040 |
Why?
| | Parents | 2 | 2022 | 1308 | 0.040 |
Why?
| | Language | 1 | 2023 | 283 | 0.040 |
Why?
| | Immunoglobulins | 1 | 1981 | 160 | 0.040 |
Why?
| | Inflammation | 1 | 2011 | 2737 | 0.040 |
Why?
| | Cosmetics | 1 | 2020 | 8 | 0.040 |
Why?
| | Minority Groups | 1 | 2022 | 249 | 0.040 |
Why?
| | Genotype | 1 | 2025 | 1835 | 0.040 |
Why?
| | Mutation Rate | 1 | 2018 | 25 | 0.040 |
Why?
| | Desmocollins | 1 | 2018 | 2 | 0.040 |
Why?
| | Desmogleins | 1 | 2018 | 3 | 0.040 |
Why?
| | Age of Onset | 1 | 2000 | 496 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3386 | 0.040 |
Why?
| | Mutagenesis | 1 | 2018 | 181 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2018 | 168 | 0.030 |
Why?
| | Self Care | 1 | 2020 | 365 | 0.030 |
Why?
| | Health Personnel | 1 | 2023 | 648 | 0.030 |
Why?
| | DNA Repair | 1 | 2018 | 206 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2024 | 1094 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2024 | 1887 | 0.030 |
Why?
| | Esophagus | 1 | 2018 | 248 | 0.030 |
Why?
| | Staphylococcus aureus | 1 | 2020 | 434 | 0.030 |
Why?
| | Melanocytes | 1 | 2016 | 64 | 0.030 |
Why?
| | Age Factors | 2 | 2014 | 3140 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2016 | 102 | 0.030 |
Why?
| | Alemtuzumab | 1 | 2015 | 15 | 0.030 |
Why?
| | Myeloablative Agonists | 1 | 2015 | 21 | 0.030 |
Why?
| | Busulfan | 1 | 2015 | 15 | 0.030 |
Why?
| | Vidarabine | 1 | 2015 | 30 | 0.030 |
Why?
| | Pain | 2 | 2015 | 786 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 892 | 0.030 |
Why?
| | Keratin-16 | 1 | 2015 | 2 | 0.030 |
Why?
| | Keratin-6 | 1 | 2015 | 6 | 0.030 |
Why?
| | Keratin-17 | 1 | 2015 | 4 | 0.030 |
Why?
| | Skin Cream | 1 | 2014 | 12 | 0.030 |
Why?
| | Oils | 1 | 2014 | 21 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2022 | 970 | 0.030 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 68 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2016 | 374 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2016 | 812 | 0.030 |
Why?
| | Enzymes | 1 | 2015 | 65 | 0.030 |
Why?
| | Hospitalization | 1 | 2024 | 2052 | 0.030 |
Why?
| | HIV Infections | 1 | 2009 | 2721 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2015 | 400 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2016 | 431 | 0.030 |
Why?
| | Oral Medicine | 1 | 2013 | 1 | 0.030 |
Why?
| | Lip Diseases | 1 | 2013 | 7 | 0.030 |
Why?
| | Tongue Diseases | 1 | 2013 | 9 | 0.030 |
Why?
| | Palate | 1 | 2013 | 35 | 0.030 |
Why?
| | Risk Factors | 1 | 2006 | 9745 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 756 | 0.020 |
Why?
| | Microstomia | 1 | 2012 | 1 | 0.020 |
Why?
| | Mouth Abnormalities | 1 | 2012 | 2 | 0.020 |
Why?
| | Ankyloglossia | 1 | 2012 | 2 | 0.020 |
Why?
| | Dental Enamel Hypoplasia | 1 | 2012 | 6 | 0.020 |
Why?
| | Down-Regulation | 1 | 2015 | 636 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1344 | 0.020 |
Why?
| | Ulcer | 1 | 2012 | 28 | 0.020 |
Why?
| | Back | 1 | 2011 | 11 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2014 | 433 | 0.020 |
Why?
| | Up-Regulation | 1 | 2015 | 839 | 0.020 |
Why?
| | Cicatrix | 1 | 2012 | 59 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 1199 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 316 | 0.020 |
Why?
| | Animals | 2 | 2024 | 35307 | 0.020 |
Why?
| | Therapeutics | 1 | 2011 | 14 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 419 | 0.020 |
Why?
| | Necrosis | 1 | 2011 | 231 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2014 | 526 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2015 | 758 | 0.020 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2011 | 187 | 0.020 |
Why?
| | Elastic Tissue | 1 | 2009 | 9 | 0.020 |
Why?
| | Hair Follicle | 1 | 2009 | 44 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2014 | 727 | 0.020 |
Why?
| | Resuscitation | 1 | 2011 | 236 | 0.020 |
Why?
| | Vasodilator Agents | 1 | 2011 | 326 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 385 | 0.020 |
Why?
| | Neck | 1 | 2009 | 94 | 0.020 |
Why?
| | Exons | 1 | 2010 | 341 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2015 | 1063 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 5045 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2016 | 4076 | 0.020 |
Why?
| | Arm | 1 | 2009 | 107 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2015 | 1688 | 0.020 |
Why?
| | Heart Arrest | 1 | 2011 | 320 | 0.020 |
Why?
| | Skin Diseases, Genetic | 1 | 2007 | 11 | 0.020 |
Why?
| | Preimplantation Diagnosis | 1 | 2007 | 5 | 0.020 |
Why?
| | Mice | 1 | 2024 | 16915 | 0.020 |
Why?
| | Wound Infection | 1 | 2007 | 29 | 0.020 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2007 | 49 | 0.020 |
Why?
| | Darbepoetin alfa | 1 | 2006 | 2 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 7055 | 0.020 |
Why?
| | Prognosis | 1 | 2014 | 3772 | 0.020 |
Why?
| | Malnutrition | 1 | 2007 | 79 | 0.020 |
Why?
| | Fetal Diseases | 1 | 2007 | 158 | 0.020 |
Why?
| | Syndrome | 1 | 2005 | 339 | 0.010 |
Why?
| | Primary Health Care | 1 | 2014 | 1678 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2013 | 1896 | 0.010 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 338 | 0.010 |
Why?
| | Immunoglobulin M | 1 | 1981 | 276 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1715 | 0.010 |
Why?
|
|
Bruckner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|